2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1589

Obesity and Rehabilitation Outcomes After Lower Extremity Arthroplasty
Abstract Number: 2411

Obesity Is Associated with Higher Levels of Fatigue in RA
Abstract Number: 1093

Obesity Is Not a Risk Factor for Poor Pain and Function Two Years After Total Knee Replacement
Abstract Number: 1846

Observation of Persistence Rates and Potential Costs Savings Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis in England, Wales and Northen Ireland Clinical Practice
Abstract Number: 1169

Obstetrical Complications in Women with Juvenile Idiopathic Arthritis
Abstract Number: 1220

Occurrence and Morbidity of Lower Extremity Ulcer in Rheumatoid Arthritis – A Population Based Study
Abstract Number: 1811

On the Origin of the Type I Interferon Signature in Rheumatoid Arthritis
Abstract Number: 1331

Once Daily High Dose Regimens of GLPG0634 in Healthy Volunteers Are Safe and Provide Continuous Inhibition of JAK1 but Not JAK2
Abstract Number: 1693

Oncogenic Activation of MAPK in Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 1317

One-Year Results From the Canadian Methotrexate and Etanercept Outcome Study: A Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in Rheumatoid Arthritis
Abstract Number: 1799

ONO-4059 – A Novel Small Molecule Bruton’s Tyrosine Kinase (Btk) Inhibitor, Suppresses Osteoclast Differentiation and Activation
Abstract Number: 1308

Opportunistic Infections in Patients with Rheumatoid Arthritis Treated with Rituximab : Data From the Autoimmunity and Rituximab Registry
Abstract Number: 710

Optical Density Measure of the Papillary Dermis Discriminates As Abnormal Clinically Uninvolved Skin in Systemic Sclerosis and Correlates with Severity of Skin Thickness
Abstract Number: 1569

Optimizing Care for Patients with Rheumatoid Arthritis Newly Treated with Biologics by Evaluating Health Status with AIMS-2
Abstract Number: 341

Oral Administration of a Novel Small Molecule BET Bromodomain Inhibitor, RVX-297, Reduces Disease Severity in a Rat Collagen-Induced Arthritis Model

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].